Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	PolarityTE	Kiromic BioPharma	Windtree Therapeutics	Brickell Biotech	Genetic Technologies
Symbol	NASDAQ:PTE	NASDAQ:KRBP	NASDAQ:WINT	NASDAQ:BBI	NASDAQ:GENE
Price Information
Current Price	$0.91	$8.50	$2.14	$0.84	$3.85
52 Week Range	Buy	N/A	Buy	Buy	N/A
MarketRank™
Overall Score	1.4	1.0	2.3	1.5	0.4
Analysis Score	3.3	0.0	3.5	3.5	0.0
Community Score	2.7	5.0	5.0	1.3	1.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	1.7	1.7	0.0
Earnings & Valuation Score	1.3	0.0	1.3	1.3	0.0
Analyst Ratings
Consensus Recommendation	Buy	N/A	Buy	Buy	N/A
Consensus Price Target	$4.00	N/A	$12.25	$5.50	N/A
% Upside from Price Target	341.70% upside	N/A	472.43% upside	551.50% upside	N/A
Trade Information
Market Cap	$104.20 million	$63.80 million	$54.62 million	$55.02 million	$56.96 million
Beta	1.29	N/A	0.25	0.34	2.65
Average Volume	7,952,370	21,664	332,614	3,485,282	1,915,424
Sales & Book Value
Annual Revenue	$5.65 million	N/A	$200,000.00	$7.92 million	$10,000.00
Price / Sales	19.39	N/A	280.95	7.13	5,785.78
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.42 per share	N/A	$5.48 per share	$0.97 per share	$0.65 per share
Price / Book	0.64	N/A	0.39	0.87	5.92
Profitability
Net Income	$-92,490,000.00	N/A	$-27,480,000.00	$-23,880,000.00	$-4,090,000.00
EPS	($3.70)	N/A	($2.52)	($5.11)	N/A
Trailing P/E Ratio	N/A	0.00	N/A	N/A	0.00
Forward P/E Ratio	N/A	∞	N/A	N/A	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-674.12%	N/A	N/A	-990.67%	N/A
Return on Equity (ROE)	-169.92%	N/A	-43.46%	-187.45%	N/A
Return on Assets (ROA)	-105.62%	N/A	-26.55%	-114.85%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.08%	N/A	0.18%	N/A	0.02%
Current Ratio	3.22%	N/A	2.75%	3.50%	10.88%
Quick Ratio	3.11%	N/A	2.75%	3.50%	10.81%
Ownership Information
Institutional Ownership Percentage	16.51%	N/A	1.59%	5.93%	1.39%
Insider Ownership Percentage	5.50%	N/A	14.91%	10.30%	N/A
Miscellaneous
Employees	153	19	31	13	N/A
Shares Outstanding	120.97 million	7.33 million	26.26 million	66.93 million	15.03 million
Next Earnings Date	5/10/2021 (Estimated)	6/30/2021 (Estimated)	5/13/2021 (Estimated)	5/12/2021 (Estimated)	N/A
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	If You’re Not Bullish on Applied Genetic Technologies Corporation (NASDAQ:AGTC) Now, You’ll Kick Yourself Later stocksregister.com - April 20 at 1:26 PM
	NGS Sample Preparation Market Size, Growth, Trends, Demand, Applications, Types, Technology, Industry Analysis and Forecasts Research Report 2027 sbwire.com - April 13 at 4:16 PM
	Genetic Technologies Limited (GENE) investors to reap big returns again marketingsentinel.com - April 13 at 11:16 AM
	Will current price volatility hamper Applied Genetic Technologies Corporation (AGTC) future potential? marketingsentinel.com - April 12 at 12:35 PM
	What Is Going On With Applied Genetic Technologies Corporation (NASDAQ:AGTC)? stocksregister.com - April 12 at 12:35 PM
	Genetic Technologies Limited [GENE] moved up 6.53: Why It’s Important dbtnews.com - April 12 at 12:35 PM
	Company News for Apr 12, 2021 finance.yahoo.com - April 12 at 12:35 PM
	Genetic Technologies Limited (NASDAQ:GENE) Stock Sentiment Check: What Does Wall Street Say? stocksregister.com - April 12 at 7:35 AM
	Genetic Link Discovered Between Face and Brain Shape scitechdaily.com - April 11 at 2:38 PM
	Advanced computer model could lead to improvements in 'bionic eye' technology news-medical.net - April 11 at 2:38 PM
	Genetic Engineering 2.0: An On-Off Switch for Gene Editing scitechdaily.com - April 11 at 2:38 PM
	Genetic Technologies Provides Update on COVID-19 Risk Test Launch finance.yahoo.com - April 9 at 11:58 AM
	Advanced Analytics Advancing Development of Genetic Vaccines contractpharma.com - March 29 at 3:40 PM
	Genetic Technologies Limited (NASDAQ:GENE) Has Recovered 65.39% So Far, But Another 145.82% Gain Cannot Be Ruled Out marketingsentinel.com - March 27 at 2:38 PM
	Is Applied Genetic Technologies Corporation (NASDAQ:AGTC) Still A Good Investment? stocksregister.com - March 26 at 10:06 AM
	BIO Letter to DEFRA Consultation on the Regulation of Genetic Technologies bio.org - March 18 at 7:35 AM
	Applied Genetic Technologies Corp. (NASDAQ: AGTC) Featured in Virtual Coverage of the 33rd Annual ROTH Conference marketwatch.com - March 17 at 9:31 AM
	Animal Genetics Market High Demand, Recent Trends, Future Growth, Business Scenario, Product, Technology, Share and Forecasts 2020 - 2027 marketwatch.com - March 15 at 10:26 PM
	Genetic Technologies pairs up with Infinity Biologix for COVID-19 risk test bioworld.com - March 5 at 6:59 PM
	Fact Check-The COVID-19 vaccine does not change recipients’ genetic makeup reuters.com - March 5 at 8:58 AM
	Could science of genetic genealogy help solve Jonathan Foundling case? onlineathens.com - March 4 at 10:23 AM
	Global Genetic Toxicology Testing Market Size, Share, Value, and Competitive Landscape 2021 marketwatch.com - March 3 at 7:04 PM
	Johnson & Johnson’s vaccine uses different technology than Moderna, Pfizer’s thedenverchannel.com - March 3 at 9:02 AM
	Biden’s Top Science Nominee Advocated ‘Preimplantation Genetic Testing’ to Decide Which Human Embryo to Keep cnsnews.com - March 3 at 9:02 AM
	How Genetic Testing Can Impact Health and Wellness news.yahoo.com - March 3 at 9:02 AM

Date	Company	Brokerage	Action
11/10/2020	PolarityTE	Cantor Fitzgerald	Reiterated Rating
9/8/2020	PolarityTE	Oppenheimer	Reiterated Rating
7/24/2020	PolarityTE	Northland Securities	Reiterated Rating
5/12/2020	PolarityTE	HC Wainwright	Reiterated Rating
11/13/2019	PolarityTE	Piper Jaffray Companies	Lower Price Target
5/13/2019	PolarityTE	National Securities	Lower Price Target
6/26/2020	Windtree Therapeutics	LADENBURG THALM/SH SH	Initiated Coverage
8/28/2020	Brickell Biotech	Lake Street Capital	Initiated Coverage

(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources